Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
Following the creation of the UK’s National Institute for Health and Care Excellence (NICE) in 1999, a cost-effectiveness threshold of…
13 Nov 2025
Estonia’s digital health DNA: Trust, data, and biotech in focus
With just 1.3 million residents, Estonia’s digital footprint far exceeds its size. When Barack Obama visited Tallinn in 2014, he wryly noted that he “should have called the Estonians” when…
10 Nov 2025
Psychedelics potential set to extend beyond mental health
Psychedelics have a long and rich history in human culture, with archaeologists estimating that humans first started consuming psychoactive mushrooms more than 16,500 years ago. While their roots in culture…
30 Oct 2025
Magazine: Cleanroom chronicles
With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being fundamentally reshaped. This month's cover feature examines what innovations regulation and cell and gene…
16 Oct 2025
From Nobel to next-gen: Sweden’s quiet life sciences ascent
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every year since 1901 in eager anticipation of the Nobel Prize…
13 Oct 2025
New US biotech hubs show potential amid onshoring requests
The US has always been a key player in the pharmaceutical industry, with prominent names like Pfizer, Eli Lilly and Bristol Myers Squibb (BMS) all becoming market pioneers in the…
10 Oct 2025
Pharma R&D set to endure despite rising MFN costs
Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally, a…